Key result
The HLA-DR3 antigen was associated with a significantly decreased risk of idiopathic dilated cardiomyopathy compared with controls (OR 0.72; 95% CI 0.58-0.90; P=0.004).
Why the study?
Does the presence of the HLA-DR3 antigen reduce the risk of idiopathic dilated cardiomyopathy?
Population
11,761 individuals pooled from 19 case-control studies.
Comparison
Presence of HLA-DR3 antigen/allele vs Absence of HLA-DR3 antigen/allele
Design
Meta-analysis
Authors
Loading...
HLA-DR3 may mark lower IDC susceptibility for risk assessment; extends genetic association data for cardiomyopathy research.
Meta-Analysis (n=11,761)
Does the presence of the HLA-DR3 antigen reduce the risk of idiopathic dilated cardiomyopathy?
Odds Ratio: 0.72 (95% CI 0.58–0.9)
p-value: p=0.004
The presence of the HLA-DR3 antigen is associated with a significantly decreased risk of idiopathic dilated cardiomyopathy, suggesting a protective genetic effect.
Jin et al. (2016) conducted a meta-analysis in Idiopathic dilated cardiomyopathy (n=11,761). HLA-DR3 antigen vs. Controls was evaluated on Idiopathic dilated cardiomyopathy risk (OR 0.72, 95% CI 0.58-0.90, p=0.004). The HLA-DR3 antigen was associated with a significantly decreased risk of idiopathic dilated cardiomyopathy compared with controls (OR 0.72; 95% CI 0.58-0.90; P=0.004).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: